FLUO.ST Stock - FluoGuide A/S
Unlock GoAI Insights for FLUO.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $385,000 | $423,000 | $6.51M | $9.61M | N/A |
| Gross Profit | $385,000 | $423,000 | $6.51M | $9.61M | N/A |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | N/A |
| Operating Income | $-32,583,000 | $-43,659,000 | $-32,211,000 | $-28,809,000 | $-22,161,000 |
| Net Income | $-28,959,000 | $-38,377,000 | $-27,342,000 | $-23,770,000 | $-17,460,000 |
| Net Margin | -7521.8% | -9072.6% | -419.9% | -247.3% | N/A |
| EPS | $-2.23 | $-3.22 | $-2.33 | $-2.15 | $-1.78 |
FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.
Visit WebsiteEarnings History & Surprises
FLUO.STEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 26, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | — | — | — | — |
Q4 2025 | Nov 27, 2025 | — | $-0.93 | — | — |
Q3 2025 | Aug 28, 2025 | — | $-0.99 | — | — |
Q2 2025 | May 28, 2025 | — | $-0.96 | — | — |
Q1 2025 | Feb 26, 2025 | — | $-0.98 | — | — |
Q4 2024 | Nov 28, 2024 | — | $-0.62 | — | — |
Q3 2024 | Aug 29, 2024 | — | $-0.88 | — | — |
Q1 2024 | Mar 20, 2024 | — | $-0.96 | — | — |
Q1 2024 | Feb 28, 2024 | — | $-1.52 | — | — |
Q4 2023 | Nov 29, 2023 | — | $-1.21 | — | — |
Q2 2023 | May 31, 2023 | — | $-0.95 | — | — |
Q2 2023 | May 29, 2023 | — | $-1.23 | — | — |
Q1 2023 | Feb 28, 2023 | — | $-1.33 | — | — |
Q4 2022 | Nov 24, 2022 | — | $-0.87 | — | — |
Q3 2022 | Aug 25, 2022 | — | $-0.70 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-0.48 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.96 | — | — |
Q4 2021 | Nov 15, 2021 | — | $-0.97 | — | — |
Q3 2021 | Aug 25, 2021 | — | $-0.55 | — | — |
Latest News
Frequently Asked Questions about FLUO.ST
What is FLUO.ST's current stock price?
What is the analyst price target for FLUO.ST?
What sector is FluoGuide A/S in?
What is FLUO.ST's market cap?
Does FLUO.ST pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to FLUO.ST for comparison